LONDON, Oct. 10, 2023 /PRNewswire/ -- Medical technology innovator Oncotech Nordic AB, awarded CE marking in 2022 for its mobile cancer and diabetes type 2 health screening app, Ophtascan™, is being launched in Romania for the first time this autumn through a new partnership with Medical Express Romania..

伦敦，2023年10月10日/PRNewswire/-医疗技术创新者Oncotech Nordic AB，于2022年为其移动癌症和糖尿病2型健康筛查应用程序Ophtascan授予CE标志™, 今年秋天通过与Medical Express罗马尼亚的新合作伙伴关系首次在罗马尼亚推出。。

Continue Reading

继续阅读

CEO Laurentiu Chideanu (top left) and senior management team at Medical Express Romania

首席执行官Laurentiu Chideanu（左上）和罗马尼亚Medical Express的高级管理团队

The mobile screening app is already being trialled and launched by doctors and patients in Central Africa, where there is huge demand for cancer and diabetes type 2 screening and diagnostics. The Ophtascan™ app is currently being used by Sigma Africa clinicians in the Central African region and product launch activities are activated in the Asian markets..

移动筛查应用程序已经在中非的医生和患者中进行试验和推出，那里对癌症和糖尿病2型筛查和诊断有着巨大的需求。Ophtascan™ app目前正在中非地区的Sigma非洲临床医生中使用，产品推出活动在亚洲市场启动。。

Using the app, physicians can use their own smartphone devices to photograph the iris of their patients and upload images to the Oncotech server.  The Oncotech AI diagnostic and machine learning system then sends the results back to the clinician within just 45 seconds.

使用该应用程序，医生可以使用自己的智能手机设备拍摄患者的虹膜并将图像上传到Oncotech服务器。Oncotech AI诊断和机器学习系统然后在45秒内将结果发送回临床医生。

The test is non-invasive, quick and requires minimal equipment, meaning that if required, testing can take place in remote locations away from hospitals.In development by Oncotech Nordic AB since 2014, Ophtascan™ is a mobile in-real-time detection system for pre-cancerous plus all four stages of lung, cervical, breast, uterine and prostate cancers.

该测试是非侵入性的，快速且需要最少的设备，这意味着如果需要，可以在远离医院的偏远地区进行测试。自2014年以来由Oncotech Nordic AB开发，Ophtascan™是一款移动式实时检测系统，适用于癌前期以及肺癌，宫颈癌，乳腺癌，子宫癌和前列腺癌的所有四个阶段。

Ophtascan can also be used for detecting Diabetes Type 2.Romanian partnershipAndre Rafnsson, CEO of Oncotech, was the Export Manager for the global medical business Coloplast when he first met CEO Laurentiu Chideanu 25 year ago. Soon after, Medical Express Romania was established in Bucharest. The Romanian distributor specialises in medical equipment, ranging from ostomy and continence care to walking aids.CEO of Medical Express Romania, Laurentiu Chideanu, who is leading the distribution drive said, 'Ophtascan™ ushers in a new era of hope, where medical technology aligns with the collective determination to alleviate the impact of cancer and diabetes on our society.

Ophtascan也可用于检测2型糖尿病。罗马尼亚合作伙伴Andre Rafnsson是Oncotech的首席执行官，25年前首次与首席执行官Laurentiu Chideanu会面时，他是全球医疗业务Coloplast的出口经理。不久之后，Medical Express罗马尼亚在布加勒斯特成立。罗马尼亚经销商专门从事医疗设备，从造口和节制护理到助行器。领导分销驱动器的罗马尼亚Medical Express首席执行官Laurentiu Chideanu说，'Ophtascan™开创了一个希望的新时代，医疗技术与集体决心相一致，以减轻癌症和糖尿病对我们社会的影响。

Through the unwavering commitment to early detection, shown by the Ophtascan™ team and the product's transformative potential, we can pursue a healthier, cancer-resilient Romania.'In February 2023, final validation of Ophtascan™ was completed, following tests on more than 1,500 oncology patients over a three-year period.

通过对早期发现的坚定承诺，如Ophtascan所示™ 团队和产品的变革潜力，我们可以追求更健康，抗癌的罗马尼亚2023年2月，Ophtascan的最终验证™ 在三年的时间里对1500多名肿瘤患者进行了测试后完成。

The scanning precision success rate was over 95 per cent, and last year reached a 97 per cent precision scanning rate, as additional patients were tested and data was validated on a daily basis.Oncotech Nordic AB CEO Andre Rafnsson concluded, 'Romania is the first of what will be several new telemedicine and remote health diagnostic business partners in Europe, Asia and BRICS countries, with the ultimate aim being to license the Ophtascan™ techno.

扫描精度成功率超过95%，去年达到97%的精确扫描率，因为额外的患者进行了测试，数据每天都在验证。Oncotech Nordic AB首席执行官Andre Rafnsson总结说：“罗马尼亚将成为欧洲，亚洲和金砖国家几个新的远程医疗和远程健康诊断业务合作伙伴中的第一个，最终目标是获得Ophtascan许可™techno。